We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > NK

News List

Novel natural killer cell engager therapy shows promise in Phase I trials europeanpharmaceuticalreview
April 15, 2021
GTB-3550 TriKE™ monotherapy was found to restore natural killer cell function and immune surveillance in relapsed or refractory AML and MDS cancer patients.
Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer prnasia
March 09, 2021
Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, announced that it has entered into an exclusive license and collaboration agreement with Shanghai-based ...
NK Ingredients' Singapore site receives EXCiPACT GMP certification newsnow
June 15, 2017
EXCiPACT is delighted to announce that the NK Ingredients Singapore site has recently been awarded an EXCiPACT certificate from SGS, one of EXCIPACT’s internationally recognised certification bodies.